MBX vs MDGL Stock Comparison

MBX currently leads MDGL in this stock comparison, with AIQ scores of 68 vs 57. The clearest difference is momentum, while MDGL has the stronger risk resilience profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 11 points
MBX
Healthcare
vs
MDGL
Healthcare
MBX
MBX Biosciences, Inc. Common Stock
Leads
Price
$55.94
Day move
+2.62%
AIQ Score
68/100
Best edge
Momentum
Sector
Healthcare
MDGL
Madrigal Pharmaceuticals, Inc.
Price
$427
Day move
+0.51%
AIQ Score
57/100
Best edge
Risk Resilience
Sector
Healthcare

What is the main difference between MBX and MDGL?

MBX leads the current stock comparison as MBX Biosciences, Inc. Common Stock, with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

MBX Biosciences, Inc. Common Stock vs Madrigal Pharmaceuticals, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 63/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 6/10

MBX leads

MBX leads by 11 AIQ points, primarily on Momentum and Quality.

Competitive: 3 of 5 evidence groups support MBX, and its signal state is cleanly positive.

Evidence agreement: 3 of 5Comparison trend: Stable
MBX

MBX Biosciences, Inc. Common Stock

Leads
AIQ Score
68/100
AIQ Edge Score
10/10
MDGL

Madrigal Pharmaceuticals, Inc.

AIQ Score
57/100
AIQ Edge Score
6/10

The Algovestiq AIQ Score currently favors MBX over MDGL, 68 versus 57 as of Nov 15, 2026. MBX's advantage is driven primarily by stronger momentum and quality, while MDGL holds the stronger risk resilience profile. MBX also shows the stronger technical structure relative to its 50-day moving average. 3 of 5 covered evidence groups favor MBX today, and the comparison is rated Competitive on stability: analyst targets on the leader are widely dispersed. MBX lead: Stable — the AIQ differential has held near 11 points over 30 sessions.

Compare MBX Biosciences, Inc. Common Stock and Madrigal Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

MBX
+136.5%
MDGL
+76.8%

Price return comparison

Growth of $10,000, price only

MBX $23,653 · MDGL $17,675

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare MBX and MDGL against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

MBX advantage
0
MDGL advantage
  • Momentum71 vs 40
    MBX +31
  • Risk Resilience50 vs 63
    MDGL +13
  • Quality74 vs 67
    MBX +7

3 of 5 evidence groups favor MBX. MBX’s edge is concentrated in momentum and quality; MDGL keeps a meaningful risk resilience edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

MBX+1 AIQ

Largest factor move: Momentum +3

New signals

  • Accumulation Pattern — bullish, volume, medium horizon (1.59x)
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
MDGL0 AIQ

Largest factor move: Momentum -1, not enough on its own to move the overall score.

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-5.0%)
  • RSI Bullish Divergence — bullish, momentum, medium horizon

MBX's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — MBX and MDGL both carry a full feed there.

The central trade-off

MBX (MBX Biosciences, Inc. Common Stock): the stronger current systematic profile, led by momentum and quality.

MDGL (Madrigal Pharmaceuticals, Inc.): the counter-case, on risk resilience, fundamentals.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

MBX

MBX on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

MDGL

MDGL on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

MBX

MBX on the Momentum factor, by 31 points.

Lower downside

MDGL

MDGL on Risk Resilience, by 13 points.

Analyst upside

MBX

MBX on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureMBXMDGLNote
Implied upside to target+90.7%+54.5%MBX has more room
Target dispersion+61.9%+30.6%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1219Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 5 covered evidence groups favor MBX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreMBX68 vs 57
FundamentalsMDGLEPS growth -65.4% vs 195.5%; TTM ROE -13.2% vs 8.8%
ValuationNot coveredNot covered
TechnicalsMBXPrice vs 50-day 0.3% vs -10.2%; vs 200-day 20.8% vs -13.8%
Risk ResilienceMDGLRisk Resilience 50 vs 63
Analyst expectationsMBXTarget upside 90.7% vs 54.5%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of MBX and MDGL and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is moderate at 11 points.
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader's signal state is cleanly positive. (supports the conclusion holding)
  • Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on MBX.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

MBX lead: Stable — the AIQ differential has held near 11 points over 30 sessions.

May 27MBX leads above the line · MDGL leads belowNov 13
Today
MBX +11
68 vs 57
7 sessions ago
MBX +10
67 vs 57
30 sessions ago
MBX +11
68 vs 57
90 sessions ago
MBX +15
75 vs 60

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

MBX

7 bullish / 0 bearish / 2 neutral

Only MBX

  • Golden Cross Active — bullish, trend, long horizon (20.41%)
  • Accumulation Pattern — bullish, volume, medium horizon (1.59x)
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Price Reclaimed 50-Day MA — bullish, trend, medium horizon
  • TSI Bullish Crossover — bullish, momentum, short horizon
  • Uptrend Structure Active — bullish, trend, long horizon
MDGLConflicted

3 bullish / 2 bearish / 2 neutral, conflicted

Only MDGL

  • Death Cross Active — bearish, trend, long horizon (4.26%)
  • Downtrend Structure Active — bearish, trend, long horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-5.0%)
  • RSI Bullish Divergence — bullish, momentum, medium horizon

Both carry 3 more signals that do not separate them: ADX Trend Weakening, ATR Expansion - Breakout Mode, MACD Histogram Expanding Bullish.

MDGL is conflicted, so the timing case there is weaker than the score alone suggests.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

MBXConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +2.62%, AIQ +1 points).

MDGLNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.51%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1MDGL closes the Momentum gap — currently 31 points behind, the largest single contributor to MBX's edge.
  2. 2MDGL's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3MBX's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

MDGL leads on balance
MetricMBXMDGL
Revenue growth (YoY)0%18.4%
EPS growth (YoY)-65.4%195.5%
Gross margin0%91%
Operating margin0%-10.7%
Return on equity (TTM)-13.2%8.8%
Debt to equity0.010.56

Performance

MBX leads 6 of 6 windows
MetricMBXMDGL
1 week (5 sessions)8.9%6.9%
1 month (20 sessions)12.8%-5%
3 months (63 sessions)-18%-18.6%
6 months (126 sessions)72.4%-18.4%
Year to date77.4%-26.6%
1 year (252 sessions)127.4%-19.2%

Technicals

MBX has the stronger structure
MetricMBXMDGL
RSI (14)53.342.5
ADX (14)13.724.8
Price vs 50-day0.3%-10.2%
Price vs 200-day20.8%-13.8%
Volatility (1M, annualized)68.2%49.9%

Risk

MDGL is the more resilient
MetricMBXMDGL
Beta1.260.41
Sharpe ratio1.42-0.32
Sortino ratio2.43-0.46
Max drawdown-37.6%-34.3%
Current drawdown-20.9%-29.1%
Annualized volatility77.3%42.6%
Value at risk (95%)-7.1%-4.1%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, MBX or MDGL?

On the Algovestiq AIQ Score, MBX is the stronger of the two as of Nov 15, 2026, scoring 68 against MDGL's 57. The edge comes from momentum and quality. MDGL is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is MBX or MDGL the better buy right now?

MBX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor MBX over MDGL?

The composite weights Quality, Value, Momentum and Risk Resilience. MBX leads Momentum by 31 points; MDGL leads Risk Resilience by 13 points; MBX leads Quality by 7 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, MBX or MDGL?

Analyst price targets imply +90.7% upside for MBX and +54.5% for MDGL, so the Street currently favors MBX. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, MBX or MDGL?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, MBX or MDGL?

MDGL on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, MBX or MDGL?

MBX on the Momentum factor, by 31 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, MBX or MDGL?

MDGL is the more resilient of the two, so the other name carries the higher downside risk. MDGL on Risk Resilience, by 13 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is MBX more profitable than MDGL?

MDGL leads on the comparable margin measures — gross margin 0% vs 91%; operating margin 0% vs -10.7%; ttm roe -13.2% vs 8.8%.

Is MBX's lead over MDGL getting stronger or weaker?

MBX lead: Stable — the AIQ differential has held near 11 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the MBX vs MDGL verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: MDGL closes the Momentum gap — currently 31 points behind, the largest single contributor to MBX's edge; MDGL's Death Cross Active resolves — a bearish trend rule currently active against it; MBX's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about MBX and MDGL?

MBX: 7 bullish / 0 bearish / 2 neutral. MDGL: 3 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on MBX is Golden Cross Active (bullish, long horizon). On MDGL it is Death Cross Active (bearish, long horizon).

Compare MBX and MDGL with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.